Received Jul 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB056A | — |
Boostrix administration with lyophilized powder reconstituted with saline water; Boostrix administration with lyophilized powder reconstituted with saline water; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB056A, expiry date 31-AUG-2025) for prophylaxis. On 14-JUL-2025, the patient received Menveo. On 14-JUL-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: Boostrix administration with lyophilized powder reconstituted with saline water) and inappropriate dose of vaccine administered (Verbatim: Boostrix administration with lyophilized powder reconstituted with saline water). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 21-JUL-2025 The health care provider wanted to know the timeframe to repeat the dose of Menveo 2 vial after administering the lyophilized component with saline water which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The vaccine administration facility was the same as primary reporter.